Mr. Marc Lemieux reports

KDA GROUP OPENS A U.S. SUBSIDIARY AND ACCELERATES THE GROWTH OF ITS MEDHERIZE SOLUTION

KDA Group Inc. has officially opened its U.S. subsidiary to launch, starting in 2026, the commercialization of Medherize, its therapeutic monitoring platform specialized in oncology. This strategic expansion positions KDA in one of the world's largest specialty drug markets, valued at more than $243-billion (U.S.) in 2023.

In the United States, specialty drugs account for nearly 40 per cent of total prescription dispensing revenues, up from 24 per cent a decade ago, and the specialty pharmacy segment is dominated by a few major players generating between $4.6-billion (U.S.) and $73-billion (U.S.) annually. This market, several times larger than that of Canada, is experiencing sustained growth driven by the rise of at-home oral oncology treatments.

Oral specialty drugs, distributed through a network of community and specialty pharmacies, are among the most expensive therapeutic products in the world. The annual cost per patient can reach tens or even hundreds of thousands of dollars for certain targeted therapies or innovative treatments. The value-added opportunity for management and adherence solutions is therefore considerable. These drugs, essential for patients suffering from cancer, rare diseases or severe chronic conditions, represent a major economic and clinical challenge for pharmaceutical companies and public payers alike.

Medherize directly addresses this need: a software-as-a-service platform that improves therapeutic adherence, interprofessional coordination and the collection of real-world clinical data. Already deployed at Centre hospitalier universitaire de Quebec -- Universite Laval (CHU de Quebec), Hopital Saint-Sacrement, the solution has proved effective in monitoring complex oral treatments and reducing therapy discontinuations.

KDA's new U.S. subsidiary will allow Medherize to be adapted to local health care infrastructures, particularly through continuing analysis and integration with American laboratory systems, building on the company's successful integration with Dossier Sante Quebec.

"Our direct presence in the United States marks a pivotal step in our international expansion," said Marc Lemieux, chief executive officer and chairman of the board of KDA.

"Medherize addresses a universal challenge: the efficient management and monitoring of specialty oral treatments. The U.S. market is many times larger than ours, representing a major lever to showcase our technology and pharmaceutical partnerships across North America," added Mr. Lemieux.

About KDA Group Inc.

KDA Group is a leader in technological innovations and specialized software solutions (software as a service) for the health care professional market. KDA is a corporation that offers high-quality products, and has recognized and respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the health care's digital transformation, and are available for the Canadian and international markets.

We seek Safe Harbor.